Summary

KEY FINDINGS
The China botulinum toxin market is set to record a 10.31% CAGR during the forecast period, 2023-2030. Growing demand for botulinum toxin for medical and cosmetic purposes is driving the market growth in China.
MARKET INSIGHTS
Botulinum toxin has been proven effective in reducing headache frequency and severity, making it a popular treatment for chronic migraine in China. The prevalence of migraine is high, especially among the population aged between 40 and 49, which is expected to drive demand for botulinum toxin in the country.
The cosmetic use of botulinum toxin is also on the rise in China, with only two products currently cleared for marketing in the country. However, with new market players seeking to enter the Chinese market, the industry is expected to expand. For instance, Galderma received approval for Restylane products from the National Medical Products Administration in China in 2020, allowing for expanding the Restylane portfolio in the country.
As more market players emerge in China, the industry is anticipated to grow further. It presents opportunities for new players to enter the market and compete with established players. However, the country’s regulatory challenges may constrain the market’s growth during the forecast period. The rising demand for botulinum toxin for medical and cosmetic purposes in China is expected to drive market growth in the coming years.
COMPETITIVE INSIGHTS
Some of the prominent market players include Daewoong Pharmaceutical Co Ltd, AbbVie, Lanzhou Institute of Biological Products Co Ltd, Galderma, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. COUNTRY SNAPSHOT
2.3. COUNTRY ANALYSIS
2.4. SCOPE OF STUDY
2.5. CRISIS SCENARIO ANALYSIS
2.5.1. IMPACT OF COVID-19 ON BOTULINUM TOXIN MARKET
2.6. MAJOR MARKET FINDINGS
2.6.1. FAVORABLE REGULATORY APPROVALS ADD TO MARKET GROWTH
2.6.2. GROWING AWARENESS ABOUT ‘NOTOX’
2.6.3. INFLATING COSMETIC TOURISM ADDS TO THE DEMAND FOR BOTULINUM TOXIN
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. SURGE IN DEMAND FOR AESTHETIC PROCEDURES
3.1.2. RISING GERIATRIC POPULATION
3.1.3. GROWING DEMAND FOR NON-INVASIVE COSMETIC PROCEDURES
3.2. KEY RESTRAINTS
3.2.1. CONCERNS REGARDING THE ADVERSE EFFECTS OF BOTULINUM TOXIN
3.2.2. LACK OF REIMBURSEMENT POLICIES SUPPORTING COSMETIC PROCEDURES
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.2. PESTLE ANALYSIS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.4.1. GROWTH PROSPECT MAPPING FOR CHINA
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
5. MARKET BY TYPE
5.1. TYPE A BOTULINUM TOXIN
5.2. TYPE B BOTULINUM TOXIN
6. MARKET BY USER DEMOGRAPHIC
6.1. WOMEN
6.2. MEN
7. MARKET BY APPLICATION
7.1. MEDICAL
7.1.1. CHRONIC MIGRAINE
7.1.2. MUSCLE SPASM
7.1.3. OVERACTIVE BLADDER
7.1.4. HYPERHIDROSIS
7.1.5. OTHER MEDICAL APPLICATIONS
7.2. AESTHETIC
7.2.1. CROW’S FEET
7.2.2. FOREHEAD LINES
7.2.3. FROWN LINES/GLABELLAR
7.2.4. SQUARE JAW/MASSETER
7.2.5. OTHER AESTHETIC APPLICATIONS
8. MARKET BY END-USER
8.1. SPECIALTY AND DERMATOLOGY CLINICS
8.2. HOSPITALS AND CLINICS
8.3. OTHER END-USERS
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. ACQUISITIONS
9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
9.1.3. PARTNERSHIPS
9.1.4. BUSINESS EXPANSIONS
9.2. COMPANY PROFILES
9.2.1. ABBVIE
9.2.1.1. COMPANY OVERVIEW
9.2.1.2. PRODUCT LIST
9.2.1.3. STRENGTHS & CHALLENGES
9.2.2. DAEWOONG PHARMACEUTICAL CO LTD
9.2.2.1. COMPANY PROFILE
9.2.2.2. PRODUCT LIST
9.2.2.3. STRENGTHS & CHALLENGES
9.2.3. EVOLUS INC
9.2.3.1. COMPANY OVERVIEW
9.2.3.2. PRODUCT LIST
9.2.3.3. STRENGTHS & CHALLENGES
9.2.4. GALDERMA
9.2.4.1. COMPANY OVERVIEW
9.2.4.2. PRODUCT LIST
9.2.4.3. STRENGTHS & CHALLENGES
9.2.5. LANZHOU INSTITUTE OF BIOLOGICAL PRODUCTS CO LTD
9.2.5.1. COMPANY OVERVIEW
9.2.5.2. PRODUCT LIST
9.2.5.3. STRENGTHS & CHALLENGES